Assessing the Impact of Using Heparin and Bivalirudin on Clinical Outcome of Subjects Undergoing Percutaneous Coronary Intervention: A Meta-Analysis.

Background: Bivalirudin is increasingly used as an alternative to heparin in patients undergoing percutaneous coronary intervention (PCI) due to its potential for reducing adverse clinical outcomes. This meta-analysis aimed to compare the effectiveness and safety of bivalirudin versus heparin across...

Descripción completa

Detalles Bibliográficos
Publicado en:Iranian Journal of Public Health Vol. 54; no. 12; pp. 2579 - 2595
Autores principales: Yu, Yan, Sun, Xiaojian, Su, Mengchao
Formato: meta analysis research systematic review tables/charts Journal Article
Publicado: Tehran University of Medical Sciences Dec2025
Acceso en línea:Ver este registro en EBSCOhost
fields @attributes:
  recordID: 1
pdfLink:
plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=191502579&site=ehost-live
header:
  @attributes:
    shortDbName: ccm
    uiTerm: 191502579
    longDbName: CINAHL Complete
    uiTag: AN
  controlInfo:
    bkinfo:
    dissinfo:
    jinfo:
      jid:
        22516085
        6N6F
      jtl: Iranian Journal of Public Health
      issn: 22516085
      maglogo: N
    pubinfo:
      dt: Dec2025
      vid: 54
      iid: 12
      pid: 21783
      pub: Tehran University of Medical Sciences
    artinfo:
      ui:
        191502579
        191502579
        191502579
        10.18502/ijph.v54i12.20812
        191502579
      ppf: 2579
      ppct: 16
      formats:
      tig:
        atl: Assessing the Impact of Using Heparin and Bivalirudin on Clinical Outcome of Subjects Undergoing Percutaneous Coronary Intervention: A Meta-Analysis.
      aug:
        au:
          Yu, Yan
          Sun, Xiaojian
          Su, Mengchao
        affil: Department of Cardiac Intensive Care Unit, Yantai YuHuangDing Hospital, Yantai, Shandong, China
      sug:
        subj:
          Bivalirudin Therapeutic Use
          Heparin Therapeutic Use
          Percutaneous Coronary Intervention Methods
          Myocardial Infarction Drug Therapy
          Drug Efficacy
          Patient Safety
          Human
          Systematic Review
          Meta Analysis
          Male
          Female
          Aged
          Aged, 80 and Over
          PubMed
          Cochrane Library
          Embase
          Checklists
          Descriptive Statistics
          Data Analysis Software
          Confidence Intervals
          Non-ST Elevated Myocardial Infarction
          Hemorrhage Mortality
          Hemorrhage Risk Factors
          Risk Assessment
          Thrombosis
          Stents
          Stroke Prevention and Control
          Anticoagulants Therapeutic Use
          Adverse Drug Event
          After Care
          Aged: 65+ years
          Aged, 80 & over
          Male
          Female
      ab: Background: Bivalirudin is increasingly used as an alternative to heparin in patients undergoing percutaneous coronary intervention (PCI) due to its potential for reducing adverse clinical outcomes. This meta-analysis aimed to compare the effectiveness and safety of bivalirudin versus heparin across various clinical outcomes. Method: A total of 27 studies were included, comprising 63,624 patients: 30,492 received Bivalirudin, and 33,132 received Heparin. Key endpoints analyzed include net adverse clinical events (NACE), major adverse clinical events, major bleeding, mortality, stroke, and stent thrombosis. Data were pooled using a randomeffects model, and heterogeneity was assessed using the I² statistic. Publication bias was evaluated using Begg's and Egger's tests. Results: Bivalirudin significantly reduced the risk of major bleeding (MD=-0.4445, 95% CI [-0.6276, -0.2615], P<0.0001, I²=76.79%) compared to Heparin. However, no significant differences were found for major adverse clinical events (MD=-0.0993, P=0.3194) or mortality (MD=-0.1959, P=0.0893). There was moderate heterogeneity in most analyses, particularly for NACE (I²=68.24%) and stent thrombosis (I²=55.33%). No significant differences were observed for stroke prevention or stent thrombosis. Subgroup analyses demonstrated significant reductions in major bleeding with Bivalirudin, particularly in STEMI patients (log OR=- 0.37, P<0.0001), though no differences in MACE or stent thrombosis were observed. High heterogeneity in NSTEMI populations (I²=81.4%) underscores the need for individualized therapy. Conclusion: Although bivalirudin significantly lowers major bleeding compared with Heparin, it shows no clear advantage in mortality or other major clinical outcomes. Substantial heterogeneity across studies indicates variability in patient populations and procedural settings. Further research is needed to define its optimal role in specific PCI subgroups.
      pubtype: Academic Journal
      doctype:
        meta analysis
        research
        systematic review
        tables/charts
        Journal Article
      ougenre: Article
    language: English
    refInfo:
    holdings:
      @attributes:
        islocal: N